Fluocinolone acetonide micro-insert intravitreous implant

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025 – – Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024 – – Announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer – – $331M of cash and investments on December 31, 2023, with cash runway through topline data of Phase 3 trials for EYP-1901 for wet AMD in 2026 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate developments. “2023 was an exceptional year of execution and results for EyePoint Pharmaceuticals. The highlights include positive data from our Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, the continued advancement of our ongoing Phase 2 trials in NPDR and DME and the strengthening of our balance sheet with a $230 million oversubscribed financing in December along with the sale of rights to YUTIQ® for $82.5 million plus future royalties last May,” said Jay Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “The DAVIO 2 clinical trial for EYP-1901 achieved all primary and secondary endpoints, highlighting its potential to become a paradigm-altering maintenance treatment for patients with wet AMD. We look forward to discussing our Phase 3 plans with the U.S. Food and Drug Administration (FDA) at a planned end of Phase 2 meeting this April and initiating the first pivotal trial in the second half of this year.” Dr. Duker continued, “We anticipate topline data for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe non-proliferative diabetic retinopathy (NPDR) in the second quarter of 2024. We are excited about the potential of EYP-1901 in NPDR, a chronic disease where over 90% of patients currently receive no course of treatment until they develop sight-threatening complications. 2024 promises to be another transformative year as we continue to advance EYP-1901 through clinical development across these three very significant indications.” R&D Highlights and Updates Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 clinical trial of EYP-1901 in wet AMD in December 2023. DAVIO 2 met all primary and secondary endpoints with both EYP-1901 doses demonstrating a statistically non-inferior change in best corrected visual acuity (BCVA) compared to aflibercept control and a favorable safety profile with no EYP-1901-related ocular or systemic serious adverse events (SAEs).DAVIO 2 Phase 2 data and sub-group analyses which underscore the favorable clinical profile of EYP-1901, were presented at Angiogenesis, Exudation, and Degeneration 2024 Meeting and at the 47th Annual Meeting of the Macula Society in February 2024.The Company plans to conduct an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in April 2024, with the initiation of the first Phase 3 pivotal trial in wet AMD expected in the second half of 2024.Announced first patient dosed in the Phase 2 VERONA clinical trial of EYP-1901 for the treatment of diabetic macular edema (DME). Topline data are expected in the first quarter of 2025.Accepted to present at the upcoming 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May. The Company will be presenting an encore presentation of the DAVIO 2 clinical trial results, the design and function of EYP-1901, plasma PK data of EYP-1901, and the mechanism of action (MOA) of vorolanib and differentiation from other anti-VEGF TKIs. Recent Corporate Highlights Announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer in March. Dr. Ribeiro joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development.Completed an upsized underwritten public offering with gross proceeds of $230.0 million in December. The Company sold 13,529,411 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,764,705 shares of common stock. The shares of common stock were sold at a public offering price of $17.00 per share. Review of Results for the Fourth Quarter Ended December 31, 2023 For the quarter ended December 31, 2023, total net revenue was $14.0 million compared to $10.5 million for the quarter ended December 31, 2022. Net product revenue for the quarter ended December 31, 2023, was $0.7 million, compared to net product revenue for the quarter ended December 31, 2022, of $9.9 million. The decrease in net product revenue resulted from the strategic exit from our commercial business in 1H 2023. Net revenue from royalties and collaborations for the quarter ended December 31, 2023, totaled $13.3 million compared to $0.7 million in the corresponding period in 2022. The increase was primarily due to partial recognition of deferred revenue from the license of the YUTIQ franchise, which beginning in 2Q 2023 will be recognized over a 2-year period in connection with the delivery of YUTIQ supply units. Operating expenses for the quarter ended December 31, 2023, totaled $30.4 million compared to $54.3 million in the prior year period. This decrease was primarily driven by the strategic exit from our commercial business in 1H 2023 and a one-time intangible asset impairment charge in 4Q 2022. Net non-operating income totaled $2.3 million and net loss was $14.1 million, or ($0.33) per share, compared to a net loss of $43.5 million, or ($1.16) per share, for the prior year period. Review of Results for the Full Year Ended December 31, 2023 For the full year ended December 31, 2023, total net revenue was $46.0 million compared to $41.4 million for the year ended December 31, 2022. Net product revenue for the full year ended December 31, 2023, was $14.2 million, compared to net product revenues for the full year ended December 31, 2022, of $39.9 million. The decrease in net product revenue resulted from the Company’s strategic exit from its commercial business in 1H 2023. Net revenue from royalties and collaborations for the full year ended December 31, 2023, totaled $31.8 million compared to $1.5 million in the corresponding period in 2022. Operating expenses for the full year ended December 31, 2023, totaled $121.1 million versus $141.0 million in the prior year period. This decrease was primarily driven by the strategic exit from our commercial business in 1H 2023 and a one-time intangible asset impairment charge in 4Q 2022. Net non-operating expense totaled $4.4 million and net loss was $70.8 million, or ($1.82) per share, compared to a net loss of $102.3 million, or ($2.74) per share, for the prior year period. Cash, cash equivalents and investments in marketable securities on December 31, 2023, totaled $331.1 million compared to $144.6 million as of December 31, 2022. Financial Outlook We expect that our cash, cash equivalents, and investments on December 31, 2023, will enable us to fund operations through topline data for the planned Phase 3 clinical trials of EYP-1901 for wet AMD in 2026. Conference Call Information EyePoint will host a conference call today at 8:30 a.m. ET to discuss the results for the fourth quarter and year ended December 31, 2023 and recent corporate developments. To access the live conference call, please register at https://register.vevent.com/register/BI91be5d0e320646e887cf4047c70fe73c. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901 and EYP-2301; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME); the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals including potential U.S. Food and Drug Administration (FDA) regulatory approval of EYP-1901 and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; the success of Durasert® as a drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Stern IR Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) December 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $281,263 $95,633 Marketable securities 49,787 48,928 Accounts and other receivables, net 805 15,503 Other current assets 9,039 9,858 Inventory 3,906 2,886 Total current assets 344,800 172,808 Operating lease right-of-use assets 4,983 6,038 Other assets 5,401 1,510 Total assets $355,184 $180,356 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $24,025 $22,278 Deferred revenue 38,592 1,205 Short-term borrowings - 10,475 Other current liabilities 646 579 Total current liabilities 63,263 34,537 Long-term debt - 29,310 Deferred revenue, less current portion 20,692 13,557 Operating lease liabilities - noncurrent 4,906 5,984 Other long-term liabilities - 600 Total liabilities 88,861 83,988 Stockholders' equity: Capital 1,007,605 766,933 Accumulated deficit (742,146) (671,351) Accumulated other comprehensive income 864 786 Total stockholders' equity 266,323 96,368 Total liabilities and stockholders' equity $355,184 $180,356 EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2023 2022 2023 2022 Revenues: Product sales, net $749 $9,857 $14,232 $39,905 License and collaboration agreements 13,029 202 30,797 362 Royalty income 250 474 989 1,137 Total revenues 14,028 10,533 46,018 41,404 Operating expenses: Cost of sales, excluding amortization of acquired intangible assets 998 3,410 4,632 8,326 Research and development 17,951 15,543 64,662 49,642 Sales and marketing 185 5,915 11,689 25,507 General and administrative 11,248 8,496 40,102 34,817 Amortization of acquired intangible assets - 205 - 2,050 Impairment of acquired intangible assets - 20,699 - 20,699 Total operating expenses 30,382 54,268 121,085 141,041 Loss from operations (16,354) (43,735) (75,067) (99,637) Other income (expense): Interest and other income, net 2,338 1,064 6,949 2,131 Interest expense - (781) (1,247) (3,189) Gain (loss) on extinguishment of debt - - (1,347) (1,559) Total other expense, net 2,338 283 4,355 (2,617) Net loss $(14,016) $(43,452) $(70,712) $(102,254) Provision for income taxes $(83) $- $(83) $- Net loss $(14,099) $(43,452) $(70,795) $(102,254) Net loss per common share - basic and diluted $(0.33) $(1.16) $(1.82) $(2.74) Weighted average common shares outstanding - basic and diluted 42,168 37,352 38,904 37,317

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. “Our outstanding fourth quarter and full year 2023 net revenue of $26.3 million and $80.8 million, respectively, mark major achievements for Alimera and are a testament to the realized vision and strong execution of our entire team in only our second full quarter marketing both ILUVIEN and YUTIQ,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “We are proud to have achieved positive Adjusted EBITDA during the fourth quarter of 2023, while maintaining a consistent net loss compared to the fourth quarter of 2022, despite facing greater interest and amortization expenses following the YUTIQ acquisition. “The success of our expanded sales team in selling both ILUVIEN and YUTIQ in the U.S. is evident, and we are further encouraged by the strong demand we continue to see in our international markets, leading us to be incredibly excited about the opportunities for sustained sales growth of both YUTIQ and ILUVIEN. As a result, we are increasing our revenue guidance for 2024 and expect to deliver over $105 million in net revenue and a greater than 20% Adjusted EBITDA margin for the full year. Additionally, we are advancing plans for potential indication expansion opportunities to broaden the number of patients that either of our long-acting steroid implants can help treat,” Mr. Eiswirth concluded. Elliot Maltz, CFO, added, “As a result of our strong revenue growth in the second half of 2023 and early in 2024, we have triggered multiple revenue-based milestone payments embedded in our debt agreements with SLR earlier than expected. To preserve cash for working capital purposes as we continue to grow ILUVIEN and YUTIQ, we are pleased to report that SLR has agreed to increase our loan facility by $5 million. Further, as a result of the full year adjusted EBITDA, we have met a major milestone to allow for an additional year of interest only payments on the loan facility.” Key Fourth Quarter Financial Highlights: Net revenue of $26.3 million up 88% vs. fourth quarter of 2022 Net loss of $3.8 million consistent with fourth quarter of 2022 Positive adjusted EBITDA of $5.0 million vs. adjusted EBITDA loss of $(1.2) million in fourth quarter of 2022 U.S. net revenue of $19.2 million up 104% vs. fourth quarter of 2022 International net revenue of $7.1 million up 54% vs. fourth quarter of 2022 Full Year 2023 Financial Highlights: Net revenue of $80.8 million up 49% vs. 2022 Net loss of $20.1 million vs. $18.1 million in 2022 Positive adjusted EBITDA of $8.7 million vs. adjusted EBITDA loss of $(7.9) million in 2022 U.S. net revenue of $56.7 million up 66% vs. 2022 International net revenue of $24.0 million up 21% vs. 2022 Corporate Highlights: Acquired U.S. commercial rights to YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, leveraging existing commercial infrastructure. Completed recruitment in the landmark NEW DAY Study for ILUVIEN, which is a multicenter, masked, randomized, controlled trial designed to generate prospective data evaluating ILUVIEN as a baseline therapy in the treatment of DME and demonstrate its potential advantages over the current standard of care of repeat anti-VEGF (aflibercept) injections. If successful, the NEW DAY Study could support a change to the current paradigm of DME treatment, offering patients a first-line, baseline treatment option that can maintain vision longer with fewer injections than other therapies. The NEW DAY Study currently has enrolled approximately 300 treatment-naïve, or near naïve, DME patients in approximately 42 sites around the U.S. Completed recruitment in the Synchronicity Study for YUTIQ, which is a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ for the treatment of macular edema associated with chronic, non-infectious uveitis affecting the posterior segment of the eye and related intraocular inflammation. Strengthened management team with additions of Jason Werner, Todd Wood and Elliot Maltz. Increased term loan agreement with its current lenders, investment affiliates managed by SLR Capital Partners, LLC, by $5 million. Achieved Adjusted EBITDA-based milestone trigger, extending the interest-only period of the Company’s term loan agreement to May of 2026 so long as the Company maintains covenant compliance. Alimera will host a conference call today at 9:00 a.m. ET to discuss these results. Details for the call can be found below. Fourth Quarter and Full Year 2023 Financial Results Net Revenue for Q4 2023 Consolidated net revenue was up 88% to approximately $26.3 million for Q4 2023, compared to $14.0 million for Q4 2022 driven by the addition of YUTIQ in the U.S. segment and continuing growth of ILUVIEN sales in the quarter. U.S. net revenue increased 104% to approximately $19.2 million for Q4 2023 compared to U.S. net revenue of $9.4 million for Q4 2022. U.S. end user demand for our fluocinolone implants in Q4 2023 was 2,065 units, up 4.4% compared to Q4 2022. International net revenue increased 52% to approximately $7.1 million in Q4 2023, compared to approximately $4.6 million in Q4 2022. Growth was driven primarily by end user demand growth of 17% in our direct markets and stocking shipments to our international distributors that were more than double that of Q4 2022. Total international segment end user demand overall was 1,464 units, down 6.5% compared to Q4 2022 due to limited inventory in our distributor markets of Spain and France during the quarter. We do not anticipate stocking issues in these markets moving forward in 2024 as our investments in ensuring available manufacturing capacity have led to significant shipments being made to both distributors late in Q4 2023. Net Revenue for FY 2023 For 2023, consolidated net revenue increased 49% to approximately $80.8 million, compared to approximately $54.1 million in 2022. The 2023 increase was primarily attributable to (a) the acquisition of YUTIQ in the United States in May and (b) strong growth in our international segment. For 2023, U.S. net revenue increased 66%, or approximately $22.5 million, to $56.7 million compared to $34.2 million in 2022. The increase was attributable to the acquisition of YUTIQ in May of 2023 and the continued growth of ILUVIEN. For 2023, international net revenue increased 21% to approximately $24.0 million for 2023, compared to approximately $19.9 million in 2022. The increase in product revenue was primarily due to increasing growth in the international markets where we sell ILUVIEN directly and improving demand from our international distributor partners. Operating Expenses Total operating expenses were approximately $22.0 million for Q4 2023, compared to approximately $14.2 million for Q4 2022. Total operating expenses for 2023 were approximately $71.8 million compared to approximately $57.9 million in 2022. The increase in 2023 was primarily attributable to the increased operating costs associated with the addition of YUTIQ in the U.S. segment and depreciation and amortization associated with the assets acquired. Net Loss Net loss for Q4 2023 was $(3.8) million, compared to net loss of approximately $(3.8) million for Q4 2022. For 2023, net loss totaled approximately $(20.1) million compared to a net loss of approximately $(18.1) million in 2022. Basic and diluted net loss per share for Q4 2023 was approximately $(0.07) compared to basic and diluted net loss per share of $(0.54) for Q4 2022. Basic and diluted net loss per share for 2023 was $(0.79) compared to basic and diluted net loss per share for 2022 of $(2.59). Adjusted EBITDA Adjusted EBITDA, a non-GAAP financial measure defined below, was approximately $5.0 million for Q4 2023, compared to negative adjusted EBITDA of approximately $(1.2) million for Q4 2022. For 2023, Adjusted EBITDA was approximately $8.7 million compared to an adjusted EBITDA loss of approximately $(7.9) million for 2022. Cash and Cash Equivalents As of December 31, 2023, Alimera had cash and cash equivalents of approximately $12.1 million, compared to $5.3 million as of December 31, 2022 and $8.3 million as of September 30, 2023. Definition of Non-GAAP Financial Measure For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, losses on extinguishment of debt, severance expenses and change in fair value of warrant asset. Please refer to the sections of this press release entitled “Non-GAAP Financial Measure” and “Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures –GAAP Net Income or Loss to Non-GAAP Adjusted EBITDA.” ALIM Call Details - Fourth Quarter and Full Year 2023 Earnings and Business Update Conference Call to Be Held March 7, 2024 A live conference call will be hosted today, at 9:00 a.m. EST by Rick Eiswirth, President and Chief Executive Officer, and Elliot Maltz, Chief Financial Officer, to discuss Alimera’s financial results and provide an update on corporate developments. Please refer to the information below for conference call dial-in information and webcast registration. Conference date: Thursday, March 7, 2024, 9:00 a.m. EST Conference dial-in: 844-839-2190 International dial-in: 412-717-9583 Conference Call Name: Alimera Sciences (Nasdaq: ALIM) Fourth Quarter and Full Year 2023 Earnings and Business Update Conference Call Pre-registration: Participants are asked to pre-register for the call by navigating to: Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast which is also available via the company’s website. Live Webcast URL: A replay will be available on Alimera’s website, under “Investor Relations” one hour following the live call and will remain available until June 7, 2024. Conference Call replay: US Toll Free: 1-877-344-7529 International Toll: 1-412-317-0088 Canada Toll Free: 855-669-9658 Replay Access Code: 3648198 End Date: March 21, 2024 Webcast Replay End Date: June 7, 2024 About Alimera Sciences, Inc. Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit . Non-GAAP Financial Measure This press release contains a discussion of a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimera’s operating performance. Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three and twelve months ended December 31, 2023 and 2022 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Measures to Non-GAAP Adjusted Measures – GAAP Net Income or Loss to Non-GAAP Adjusted EBITDA.” GAAP net income or loss is the most directly comparable GAAP financial measure to Adjusted EBITDA. Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies may calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies. The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure. Forward Looking Statements This press release contains, and the conference call in which executives of Alimera will discuss this press release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to its business strategy, future operations, future financial position, outlook and guidance, Alimera’s prospects, plans and objectives, and timing and outcome of its clinical trials. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplates,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties (some of which are beyond Alimera’s control), including factors that could delay, divert or change these expectations, and could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of (i) Alimera’s most recently filed Annual Report on Form 10-K for the year ended December 31, 2022, and (ii) Alimera’s most recently filed Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2023, all of which are on the SEC and are available on the SEC’s website at . The expected financial results discussed in this press release are preliminary and unaudited and represent the most current information available to Alimera’s management, as financial closing procedures for the three months and full year ended December 31, 2023 are not yet complete. These estimates are not a comprehensive statement of Alimera’s financial results for the fourth quarter and the full year, and actual results may differ materially from these estimates as a result of the completion of quarter-end financial reporting process and the subsequent occurrence or identification of events prior to the formal issuance of the audited financial statements for the full year ended December 31, 2023. All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely on the forward-looking statements Alimera makes or that are made on its behalf as predictions of future events. These forward-looking statements speak only as of the date of this press release. Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Therefore, you should not rely on these forward-looking statements as representing Alimera’s views as of any date after today. For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com For media inquiries: Jules Abraham for Alimera Sciences julesa@coreir.com ALIMERA SCIENCES, INC. CONSOLIDATED BALANCE SHEETS (In thousands, unaudited) December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 12,058 $ 5,274 Restricted cash 32 30 Accounts receivable, net 34,545 19,612 Prepaid expenses and other current assets 3,909 2,892 Inventory 1,879 1,605 Total current assets 52,423 29,413 Property and equipment, net 2,466 2,525 Right of use assets, net 1,124 1,395 Intangible asset, net 97,355 8,957 Deferred tax asset 104 129 Warrant asset 52 183 Total assets $ 153,524 $ 42,602 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 8,253 $ 10,088 Accrued expenses 6,193 3,998 Accrued licensor payments 7,275 - Notes payable - 25,313 Finance lease obligations 194 333 Total current liabilities 21,915 39,732 Notes payable 64,489 18,683 Accrued licensor payments 15,136 - Other non-current liabilities 5,815 4,995 Total liabilities 107,355 63,410 Stockholders' equity (deficit): Preferred stock: Series A convertible preferred stock - 19,227 Common stock 524 70 Common stock warrants 4,396 - Additional paid-in capital 462,446 378,238 Accumulated deficit (418,491 ) (415,388 ) Accumulated other comprehensive loss (2,706 ) (2,955 ) Total stockholders' equity (deficit) 46,169 (20,808 ) Total liabilities stockholders' equity (deficit) $ 153,524 $ 42,602 ALIMERA SCIENCES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2023 2022 2023 2022 Net revenue $ 26,306 $ 14,029 $ 80,754 $ 54,129 Cost of goods sold, excluding depreciation and amortization (3,626 ) (2,125 ) (10,837 ) (7,977 ) Gross profit 22,680 11,904 69,917 46,152 Operating expenses: Research, development and medical affairs expenses 4,769 4,230 16,626 16,228 General and administrative expenses 6,379 3,491 18,530 13,028 Sales and marketing expenses 7,768 5,765 27,946 25,987 Depreciation and amortization 3,040 683 8,747 2,706 Total operating expenses 21,956 14,169 71,849 57,949 Income (loss) from operations 724 (2,265 ) (1,932 ) (11,797 ) Interest expense and other, net (4,754 ) (1,634 ) (10,185 ) (5,881 ) Unrealized foreign currency gain, net 274 170 116 249 Loss on extinguishment of debt - - (1,079 ) - Change in fair value of common stock warrant - - (6,836 ) - Change in fair value of warrant asset (18 ) (52 ) (131 ) (650 ) Net loss before income taxes (3,774 ) (3,781 ) (20,047 ) (18,079 ) Income tax (provision) benefit (7 ) 1 (85 ) (28 ) Net loss $ (3,781 ) $ (3,780 ) $ (20,132 ) $ (18,107 ) Preferred stock dividends - - (1,259 ) - Net loss applicable to common shareholders $ (3,781 ) $ (3,780 ) $ (21,391 ) $ (18,107 ) Net loss per share - basic and diluted $ (0.07 ) $ (0.54 ) $ (0.79 ) $ (2.59 ) Weighted average shares outstanding - basic and diluted 54,422,965 7,000,279 25,561,885 6,996,850 RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA (In thousands, unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2023 2022 2023 2022 GAAP net loss $ (3,781 ) $ (3,780 ) $ (20,132 ) $ (18,107 ) Adjustments to net loss: Interest expense, net and other 4,754 1,634 10,185 5,881 Income tax provision (benefit) 7 (1 ) 85 28 Depreciation and amortization 3,040 683 8,747 2,706 Stock-based compensation expense 805 187 1,435 910 Unrealized foreign currency exchange gain, net (274 ) (13 ) (116 ) (92 ) Loss on extinguishment of debt - - 1,079 - Change in fair value of common stock warrants - - 6,836 - Change in fair value of warrant asset 18 52 131 650 Severance expenses 461 - 461 147 Non-GAAP adjusted EBITDA $ 5,030 $ (1,238 ) $ 8,711 $ (7,877 )